MedTrace Logo

Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome

NCT02936596 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2021-10-27

No results posted yet for this study

Summary

Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome induced by ursodeoxycholic acid only or combination therapy of immunosuppressive agents

Conditions

  • Hepatitis, Autoimmune
  • Cholangitis
  • Liver Cirrhosis, Biliary
  • Cholestasis

Interventions

DRUG

Ursodeoxycholic acid combination of immunosuppressive agents

Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)

DRUG

Ursodeoxycholic Acid

Ursodeoxycholic Acid

Sponsors & Collaborators

  • Xiaoli Fan

    lead OTHER

Principal Investigators

  • Li Yang, MD · West China Hospital,Chengdu, Sichuan, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2022-06-01
Completion
2022-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02936596 on ClinicalTrials.gov